Is a Surprise Coming for Gilead Sciences (GILD) This Earnings Season?Zacks Investment Research • 08/01/22
Biktarvy® Demonstrates High Efficacy for a Broad Range of People Initiating Treatment for HIV, Including Those With HBV CoinfectionBusiness Wire • 07/28/22
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 07/26/22
Kite's CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)Business Wire • 07/22/22
CHMP Adopts Positive Opinion Recommending Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients With COVID-19Business Wire • 07/22/22
Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV EpidemicBusiness Wire • 07/21/22
Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health EquityBusiness Wire • 07/20/22
Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir)Business Wire • 07/19/22
Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022Business Wire • 07/12/22
Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General CounselBusiness Wire • 07/12/22
Kite's CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular LymphomaBusiness Wire • 06/28/22